First Participant in Israel Enrolled in Phase 3 MDMA-Assisted Therapy Study in Israel

On June 11, 2021, the first participant in Be’er Ya’akov (Merhavim), Israel, was enrolled in our randomized, double-blind, placebo-controlled, multi-site Phase 3 study of the efficacy and safety of manualized MDMA-assisted therapy for the treatment of severe posttraumatic stress disorder).

This study will assess the efficacy and safety of MDMA-assisted psychotherapy versus psychotherapy with placebo control in participants diagnosed with at least moderate PTSD.